Introduction
============

Metastatic disease involving the stomach is a rare event. The lifetime prevalence is only 0.7-1.7% in patients with known malignancies ([@B1]). Common sources are breast cancer, lung cancer, esophageal cancer, renal cell carcinoma, and malignant melanoma ([@B1], [@B2]). Gastric metastasis from ovarian cancer is exceptionally rare. Only 16 cases have been reported in the English literature. We herein present the 17th case of gastric metastasis from ovarian cancer, in which a serous carcinoma of the ovary, FIGO stage IA, developed a solitary intramural metastasis 8 years later. A literature review indicated that all cases of ovarian cancer that developed a metastasis to the stomach were in stages higher than IIB, except for one case of stage IA endometrioid adenocarcinoma. Gastric metastases from stage IA ovarian serous carcinoma have never been reported.

Case Report
===========

A 71-year-old asymptomatic woman was seen for the evaluation of a gastric submucosal tumor. Eight years earlier, she had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy for ovarian cancer. Histologically, the tumor was limited to the left ovary without metastasis, and serous adenocarcinoma, grade 3 (G3), FIGO stage IA was diagnosed. Carboplatin and docetaxel were given, but she developed dyspnea, so chemotherapy was discontinued after one cycle. Afterwards, she was followed up every 6 months and remained disease-free for 8 years, when her serum CA125 and CA72-4 levels increased to 122 U/mL (reference range: \<35 U/mL) and 25.2 U/mL (reference range: \<8.0 U/mL), respectively. Computed tomography (CT) of the chest to the pelvis revealed a 29 ×24 mm submucosal mass in the gastric antrum and swelling of the perigastric and paraaortic lymph nodes. Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with CT (^18^F-FDG PET/CT) showed intense FDG uptake in the gastric mass, perigastric lymph nodes, paraaortic lymph nodes, and left supraclavicular lymph nodes ([Fig. 1](#g001){ref-type="fig"}). Upper gastrointestinal endoscopy revealed a submucosal tumor covered with normal gastric mucosa ([Fig. 2](#g002){ref-type="fig"}). Clinical differential diagnoses included malignant gastrointestinal stromal tumor (GIST) with metastases, malignant lymphoma, and gastric recurrence from ovarian carcinoma. She underwent gastric boring biopsy, the specimen from which revealed a poorly differentiated adenocarcinoma with a micropapillary component ([Fig. 3A](#g003){ref-type="fig"}). Initially, invasive micropapillary carcinoma (IMPC) of the stomach was considered; however, because of her history of ovarian cancer, the specimen was compared to the previous ovarian carcinoma. The tumor was confirmed as a metastatic serous adenocarcinoma from the ovary ([Fig. 3B](#g003){ref-type="fig"}). Immunohistochemically, both the gastric tumor and the ovarian tumor were positive for CA125, cytokeratin 7 (CK7), Wilms\' tumor 1 (WT1), estrogen receptor (ER), PAX8, and p53, whereas they were negative for progesterone receptor (PR) and cytokeratin 20 (CK20). The expression of p53 was detected in \>90% of cells in both tumors. The patient received 6 cycles of carboplatin and pegylated liposomal doxorubicin and is currently in complete remission 8 months after gastric biopsy.

![Computed tomography (CT) images combined with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT). (A) CT revealed a 29×24 mm mass in the gastric antrum (arrows) with perigastric and paraaortic lymph node swelling (arrow heads). (B) FDG-PET/CT showed intense FDG uptake in the corresponding mass and swellings.](1349-7235-56-0915-g001){#g001}

![Upper gastrointestinal endoscopy revealed a submucosal tumor covered with smooth mucosa in the gastric antrum.](1349-7235-56-0915-g002){#g002}

![Light microscopy of gastric biopsy and ovarian tumor specimens. (A) Gastric biopsy revealed an adenocarcinoma with papillary and micropapillary growth patterns (Hematoxylin and Eosin (H&E) staining, original magnification ×20). With higher magnification, the tumor cells showed high nuclear grades with high nuclear/cytoplasmic ratios (inset, H&E staining, original magnification ×40). (B) Histology of the previous ovarian tumor showed a similar growth pattern to that of the gastric tumor (H&E staining, original magnification ×20, inset ×40).](1349-7235-56-0915-g003){#g003}

Discussion
==========

We herein describe the case of a solitary gastric recurrence 8 years after the initial ovarian carcinoma was diagnosed. Although several lymph nodes appeared to be involved, no obvious metastasis to other organs or the peritoneal surface was identified. There has been no previous report in which a stage IA serous ovarian carcinoma metastasized to the stomach. The reasons for this recurrence may have been insufficient initial chemotherapy due to adverse effects in this patient, and the absence of lymph node sampling at the time of ovarian surgery, because there were no findings suggestive of lymph node metastasis by imaging and intraoperative findings.

Ovarian carcinoma usually metastasizes along the peritoneal surface. About 31-38% of ovarian cancer patients develop distant metastasis during the course of the disease, of which 8-18% are synchronous metastases ([@B3], [@B4]). The most common metastatic sites are the pleura, liver, lung, distant lymph nodes, and, less commonly, the central nervous system, skin, pericardium, bone, spleen, and breast ([@B3], [@B4]). Significant risk factors for distant metastasis development are higher stage, higher histological grade, and lymph node involvement at the time of the initial diagnosis. The median interval to metastasis is 44 months, and the median survival after distant metastasis is 12-30 months ([@B4], [@B5]). Cormio et al. reported that, in a multivariate analysis, the time interval between the diagnosis of ovarian cancer and the documentation of distant metastasis was the only significant factor for prognosis ([@B4]). Bristow et al. reported that complete cytoreductive surgery for recurrent ovarian cancer was an independent prognostic factor in their meta-analysis ([@B5]).

Metastasis from an ovarian tumor to the stomach without peritoneal seeding is extremely rare. To our knowledge, including our case, only 17 such cases have been reported in the English literature ([Table](#t001){ref-type="table"}) ([@B1], [@B6]-[@B20]). These patients ranged in age from 42-73 years (mean, 58 years). Histologically, serous carcinoma accounted for 15 cases, and endometrioid adenocarcinoma accounted for 1 case. This result may indicate that serous carcinoma predominantly leads to gastric metastasis, because the reported ratio between serous and non-serous carcinoma was about 2.8:1 for all distant metastases of ovarian carcinoma ([@B3], [@B4]). Only five reports mentioned histological grade, and all of them were serous carcinoma G3. The stages for all cases were higher than IIB, except for one endometrioid adenocarcinoma (IA) and the present case (IA). Four cases reported the stomach as the only metastatic site; five cases, including ours, had gastric and lymph node metastases; and seven cases also had metastases to other organs. The duration to gastric recurrence from the time of ovarian cancer diagnosis, excluding synchronous metastasis, ranged from 12-144 months (median, 39 months), similar to the interval for overall distant metastases. Asymptomatic patients predominated (10 patients), and the other 7 patients had some symptoms, such as abdominal pain, discomfort, and dyspepsia ([Table](#t001){ref-type="table"}). Gastric tumors had ulceration in nine cases and no ulceration in seven. In 11 cases, the serum CA125 levels were checked, and all showed elevated levels. Because the information provided in the case reports is limited and varied, survival after documentation of gastric metastasis is not conclusive at this time.

###### 

Summary of Clinicopathological Findings of Gastric Metastases from Ovarian Carcinomas.

       Reference      Age (years)   Histology                         Stage    Therapy for primary tumor                                    Recurrent organs                                                             Duration to gastric recurrence (months)   Symptoms at gastric recurrence   Ulcer   Serum CA125 at gastric recurrence   Immuno- histochemistry                                     Follow- up after gastric metasta- sis
  ---- -------------- ------------- --------------------------------- -------- ------------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------------------------- -------------------------------- ------- ----------------------------------- ---------------------------------------------------------- ---------------------------------------
  1    1              55            Serous                            ≥ IIIB   Tumor reduction +chemotherapy                                Stomach, pelvic mass                                                         20                                        Asymptomatic                     \-      NA                                  NA                                                         NA
  2    6              74            Endometrioid                      IA       TAH+BSO+LN +omentectomy +chemotherapy                        Stomach, paraaortic LNs                                                      12                                        Asymptomatic                     \-      high                                NA                                                         NA
  3    7              61            Serous, G3                        IIIC     Surgery +chemotherapy                                        Stomach, lung, liver                                                         15                                        Abdominal discomfort             \+      high                                NA                                                         6 months, DOD
  4    8              62            Poorly differentiated carcinoma   NA       Surgery +chemotherapy                                        Stomach                                                                      84                                        Belching, reflux, discomfort     \+      high                                CA125+, CKAE1/ AE3+, CK7+, CK20-, vimentin-, CD117-, CEA   NA
  5    9              42            Serous, G3                        IIIC     TAH+BSO +omentectomy +bowel nodule resection +chemotherapy   Stomach, perigastric LNs                                                     13                                        Asymptomatic                     NA      high                                NA                                                         12 months, NED
  6    10             55            Serous                            IV       TAH+BSO +omentectomy +chemotherapy                           Stomach, right adrenal gland, supraphrenic mass                              0                                         Epigastric pain, fullness        \+      high                                CK-AE1/ AE3+, CK7+, WT1+, CK20-, ER-, PR-                  12 months, NED
  7    11             49            Serous                            ≥ IIB    TAH+BSO +LNs +resection of colon metastasis +chemotherapy    Stomach                                                                      42                                        Asymptomatic                     \-      high                                NA                                                         18 months, NED
  8    12             70            Serous                            IV       NA                                                           NA                                                                           0                                         Dyspepsia                        \+      NA                                  NA                                                         NA
  9    13             61            Serous, G3                        NA       Surgery +chemotherapy                                        Stomach                                                                      144                                       Asymptomatic                     \+      high                                CA125+, CK7+, WT1+, ER+, CK20-, PR-, CDX2-                 5 months, NED
  10   14             55            Serous                            IIIB     TAH+BSO +omentectomy +chemotherapy                           Stomach, spleen, peritoneum                                                  60                                        Fatigue, melena                  \-      NA                                  ER+, PR+, p53+                                             NA
  11   15             43            Serous, G3                        IV       TAH+BSO +LNs +omentectomy +chemotherapy                      Stomach, hepatoduodenal LN                                                   0                                         Pain, perforation                \+      high                                CA125+, WT1+, CK20-                                        NA
  12   16             58            Serous                            IIIB     TAH+BSO +LNs +omentectomy +chemotherapy                      Stomach, peritoneum, omentun, pelvis, iliac perigastric LNs                  36                                        Asymptomatic                     \+      NA                                  WT1+, GCDFP-15-, CD117-                                    NA
  13   17             63            Serous                            NA       TAH+BSO +LNs +chemotherapy                                   Stomach                                                                      72                                        Asymptomatic                     \+      NA                                  CA125+, ER+, PR+                                           9 months, DOD
  14   18             73            Serous                            NA       Tumor reduction +chemotherapy                                Stomach, rectum, lymph nodes (paraaortic, perihepatic, perigastric, cecum)   84                                        Epigastric pain, dyspepsia       \+      NA                                  NA                                                         94 months, DOD
  15   19             51            Serous                            III      TAH+BSO +LNs +omentectomy +chemotherapy                      Stomach, perigastric LNs                                                     20                                        Asymptomatic                     \-      high                                WT1+, ER+, PR+, CK20-                                      NA
  16   20             51            Serous                            NA       Surgery                                                      Stomach, pancreas                                                            25                                        Asymptomatic                     \-      high                                CA125+, CK7+, ER+, PR+, CD56+, CK20-, CDX2-                NA
  17   Present case   71            Serous, G3                        I A      TAH+BSO +omentectomy +chemotherapy                           Stomach, lymph nodes (paraaorta, perigastric, left supraclavicle)            96                                        Asymptomatic                     \-      high                                CA125+, CK7+, WT1+, ER+, p53 +, PR-, CK20-                 8 months, NED

BSO: bilateral salpingo-oophorectomy, CK: cytokeratin, DOD: died of disease, ER: estrogen receptor, LN: lymphadenectomy, LNs: lymph nodes, NA: not available, NED: no evidence of disease, PR: progesterone receptor, TAH: total abdominal hysterectomy, WT1: Wilms\' tumor 1

Gastric metastasis without peritoneal seeding suggests metastasis through a hematogenous route or lymphatic spread. Despite the swelling of the paraaortic and perigastric lymph nodes, swelling of the pelvic lymph nodes was not observed in this patient. This finding supports the idea that gastric metastasis occurred through the paraaortic lymph node route ([@B6]).

Clinically, gastric metastases from ovarian cancer mimic GISTs ([@B10], [@B11], [@B19]). A GIST was suspected in the present case based on the imaging and endoscopic findings. Biopsy and pathological investigation are necessary to confirm gastric tumors as metastases. Histologically, the differential diagnosis from gastric adenocarcinoma, especially IMPC, is important. The present case also showed micropapillary architecture on histology. Our literature search did not reveal any IMPC cases covered with normal gastric mucosa without ulceration. Although a few intramural gastric adenocarcinomas have arisen from the diverticulum or ectopic pancreatic tissue ([@B21], [@B22]), the tumor cells are of the gastric or pancreaticobiliary epithelial phenotype. Clinical information and comparison with the previous ovarian cancer histology are important. In difficult cases, immunohistochemistry would further help to differentiate a metastasis from a primary gastric tumor. Specifically, a combination of PAX8, WT1, ER, CEA, and CDX2 generally resolves this issue, since PAX8, WT1, and ER are highly sensitive to ovarian adenocarcinoma, whereas CEA and CDX2 are sensitive to gastric adenocarcinoma ([@B23]-[@B25]).

In conclusion, although gastric metastasis from ovarian carcinoma is exceptionally rare, clinicians should nevertheless be aware that, in patients with a submucosal tumor and a history of ovarian cancer, gastric lesions may be secondary metastases from the ovarian cancer. For gastric metastatic lesions, complete cytoreductive surgery is recommended when possible; however, at present, it is not clear which factors most influence survival after gastric metastasis.
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